Table 1. Summary of the studies included in the systematic review.

Author	Year of publication	Countries	Completeness of ascertainment	Population coverage	Calendar period for incident cases and end of follow-up	Age span	Quality indicators	Reference classification	Estimator
Gatta et al	2003	EUROCARE-3[1] consortium	Not specified	Regional and national	1990-1994, not specified	15-24	Proportion of microscopically verified tumours, exclusions, proportion of patients censored before 5 years, proportion of unspecified morphologies	ICD-O[2]-3	Observed survival
Pearce et al	2005	England	98%	Regional: Northern Region	1968-1997, not specified	15-24	Not specified	Not specified	Observed survival
Stiller et al	2006	ACCIS[3]	Not specified	Regional and national	1978-1997, 2001	15-19	Proportion of microscopically verified tumours, exclusions, proportion of unspecified morphologies	ICD-O-2	Observed survival
Desandes et al	2007	France	Not specified	Regional (10%): 9	1978-1997, 2002	15-24	Not specified	ICD-O-2	Observed survival

				registries					
Linabery et al	2008	United States	98%	Regional (14%): SEER[4] 13	1975-1999, not specified	15-19	Proportion of microscopically verified tumours, proportion of patients lost to follow-up	ICD-O-3	Observed survival
Gatta et al	2009	EUROCARE-4[5] consortium	Not specified	Regional and national	1995-2002, 2003	15-24	Proportion of microscopically verified tumours, exclusions, proportion of unspecified morphologies	ICD-O-3	Observed survival
Aben et al	2012	Netherlands	95%	National	1989-2009, 2010	15-29	Exclusions	ICD-O - 1,2,3	Relative survival
Carreira et al	2012	Portugal	Not specified	Regional (30%): 5 districts	1997-2006, 2010	15-24	Not specified	ICD-O-3	Observed survival
Jung et al	2012	South Korea	Not specified	National	1999-2004, 2009	20-44	Proportion of microscopically verified tumours	ICD-O-3	Observed survival
Thumma et al	2012	United States	Not specified	Regional: SEER	1973-2008, not specified	20-39	Not specified	Not specified	Observed survival
Gondos et al	2013	Germany, United States	Not specified	Germany: regional (41%); United States: regional (14%)	1997-2006, not specified	15-49	Exclusions	ICD-O-3	Relative survival

Nicholson et al	2013	England	Not specified	Regional: Yorkshire	1990-2004, 2009	16-24	Not specified	Not specified	Observed survival
Ho et al	2014	Netherlands	98%	National	1989-2010, not specified	18-40	Not specified	ICD-O-3	Observed survival
Smoll et al	2014	United States	Not specified	Regional: SEER 18	2000-2006, not specified	16-39	Not specified	Not specified	Relative survival
Brodbelt et al	2015	England	Not specified	National	2007-2011, not specified	20-44	Proportion of microscopically verified tumours	ICD-O-2	Relative survival
Narita et al	2015	Japan	Not specified	Not specified	2001-2004, not specified	20-39	Not specified	Not specified	Observed survival
Visser et al	2015	EUROCARE-5[6] consortium	Not specified	Regional and national	2000-2007, 2008	15-44	Proportion of microscopically verified tumours, proportion of unspecified morphologies	ICD-O-3	Relative survival
Trama et al	2016	EUROCARE-5 consortium	Not specified	Regional and national (12-100%)	2000-2007, 2008	15-39	Proportion of microscopically verified tumours, exclusions, proportion of lost to follow-up, proportion of unspecified morphologies	ICD-O-3	Relative survival

Georgakis et al	2017	South Eastern Europe (SEE[7]) consortium, United States	Not specified	SEE consortium: regional and national (5-100%); United States: regional (28%): SEER 18	2001-2009, 2016	15-39	Proportion of microscopically verified tumours, exclusions, proportion of unspecified morphologies	ICD-O-3	Observed survival
Ostrom et al	2017	United States	Not specified	Regional (26%): SEER 18	2000-2014, not specified	15-39	Proportion of microscopically verified tumours	ICD-O-3	Relative survival

[1] EUROCARE-3 consortium: Austria, Czech Republic, Denmark, England, Estonia, Finland, France, Germany, Iceland, Italy, Malta, Netherlands, Norway, Poland, Scotland, Slovakia, Slovenia, Spain, Sweden, Switzerland, Wales

[2] ICD-O: International Classification of Diseases for Oncology

[3] ACCIS consortium: Denmark, Estonia, Finland, France, Germany, Hungary, Iceland, Italy, Netherlands, Slovakia, Slovenia, Spain, Switzerland, UK, Norway

[4] SEER: Surveillance, Epidemiology, and End Results Program

[5] EUROCARE-4 consortium: Austria, Belgium, Czech Republic, Denmark, England, Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Malta, Netherlands, Northern Ireland, Norway, Poland, Portugal, Scotland, Slovakia, Slovenia, Spain, Sweden, Switzerland, Wales

[6] EUROCARE-5 consortium: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, England, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Northern Ireland, Norway, Poland, Portugal, Scotland, Slovakia, Slovenia, Spain, Sweden, Switzerland, Wales

[7] SEE consortium: Belarus, Bulgaria, Croatia, Cyprus, Greece, Malta, Portugal, Romania, Serbia, Slovenia, Turkey, Ukraine